21:35 , Mar 18, 2019 |  BC Extra  |  Company News

Biohaven spends $105M for faster review of oral CGRP inhibitor

Biohaven bought a $105 million Priority Review voucher from GW Pharmaceuticals to expedite the entry of its oral migraine therapy into the CGRP inhibitor market. It plans to use the voucher on an NDA for...
14:06 , Mar 18, 2019 |  BC Extra  |  Financial News

Karuna looks past schizophrenia with $68M series B

Karuna intends to execute on its broader ambitions for lead program KarXT xanomeline/trospium chloride beyond schizophrenia, including development in at least two new indications, after raising $68 million in series B funding. By late 2019,...
18:05 , Mar 15, 2019 |  BC Week In Review  |  Clinical News

Lilly looks to expand Cyramza's label into first-line NSCLC

Eli Lilly said it plans to initiate global regulatory applications mid-year seeking to expand the label of Cyramza ramucirumab to include first-line treatment of metastatic non-small cell lung cancer in patients whose tumors have activating...
01:31 , Mar 15, 2019 |  BC Innovations  |  Tools & Techniques

Synthetic solutions for immuno-oncology

Synthorx Inc. is poised to enter the clinic this year with an IL-2 therapy that could validate its synthetic DNA platform. Marrying its click chemistry and unnatural amino acid technology with pegylation, the company is...
21:38 , Mar 12, 2019 |  BC Extra  |  Company News

Oxford BioMedica, Microsoft join on digital tools to optimize lentiviral production

In the latest example of how digital computing is increasingly interfacing with biomanufacturing to optimize yields and purity, Oxford BioMedica on Tuesday entered a two-year R&D collaboration with Microsoft to identify the optimal conditions for...
00:04 , Mar 9, 2019 |  BC Extra  |  Company News

Management tracks: Lundbeck hires first CBO; ICT opens U.S. office

Neurology company Lundbeck hired Keld Flintholm Jørgensen as its first CBO. Jørgensen, who will begin at H. Lundbeck A/S (CSE:LUN) April 4, is global head of strategic partnering at Roche (SWX:ROG;OTCQB:RHHBY). Innovative Cellular Therapeutics Co....
17:37 , Mar 8, 2019 |  BC Week In Review  |  Company News

Lilly's Emgality gets Priority Review for cluster headache

Lilly said FDA accepted and granted Priority Review to an sBLA for Emgality galcanezumab-gnlm to prevent episodic cluster headache in adults. A company spokesperson said the PDUFA date is in 2Q19. The humanized mAb targeting...
17:28 , Mar 8, 2019 |  BC Week In Review  |  Clinical News

Higher dose of tanezumab meets in latest Phase III pain readout

Pfizer and partner Eli Lilly reported on Feb. 19 that the 10 mg dose of tanezumab met the primary endpoint in the Phase III A4091059 trial to treat chronic low back pain. The data follow...
01:56 , Mar 8, 2019 |  BC Innovations  |  Targets & Mechanisms

Oral insulin innovation

While clinical data suggest an oral insulin product may finally be within reach, the technology struggles to compete with injectables on price and efficacy. A handful of academics and companies are pushing preclinical innovation in...
22:55 , Mar 6, 2019 |  BC Extra  |  Company News

Report: China’s Innovent prices domestic PD-1 inhibitor at smaller discount than Junshi

Innovent priced its anti-PD-1 mAb Tyvyt in China at a discount compared with the China price of Keytruda, but a premium to the price of fellow domestic PD-1 inhibitor Tuoyi from Junshi Biosciences, according to...